Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- IP High Court Reverses JPO Ruling on Lipitor Patent
December 7, 2012
- With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
- Ex-JPMA Secretary General Expresses Hope for Globalization of Domestic Pharma Industry: JPLA Seminar
December 7, 2012
- ARB Market Nearing Its Limit; No More Growth in the Second Half?
December 7, 2012
- MSD Submits NDA for Novel Insomnia Treatment Suvorexant
December 6, 2012
- Lantus Shows Low Incidence of Hypoglycemia in Combination Use with OHA: Sanofi
December 5, 2012
- Astellas Initiates Patient Enrollment in PII Trial of Tivozanib for Triple Negative Breast Cancer
December 5, 2012
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
- Hospira Applies for Irinotecan Generic for Pediatric Malignant Solid Tumors Based on Data from the Public Domain
December 4, 2012
- Novartis Concludes Comarketing Agreement with Taisho for SGLT-2 Inhibitor Luseogliflozin
December 4, 2012
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…